Indaptus Therapeutics, Inc. Operating Income
Indaptus Therapeutics, Inc. (INDP) reported Operating Income of -$1.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- Indaptus Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$1.81M.
- Indaptus Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$2.16M.
- Indaptus Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$8.16M.
- Indaptus Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$2.65M.
- Indaptus Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$19.83M.
- Indaptus Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$15.37M.
- Indaptus Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$16.38M.
- Indaptus Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$14.91M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.81M 10-Q · filed 2026-08-13 | -$3.97M 10-Q · filed 2026-08-13 | -$12.12M derived: sum of 3 quarters · filed 2026-08-13 | -$14.77M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$2.16M 10-Q · filed 2026-05-15 | -$10.32M derived: sum of 2 quarters · filed 2026-05-15 | -$12.96M derived: sum of 3 quarters · filed 2026-05-15 | -$17.42M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$10.80M derived: sum of 2 quarters · filed 2026-03-17 | -$15.26M derived: sum of 3 quarters · filed 2026-08-13 | -$19.83M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | -$2.65M 10-Q · filed 2025-11-12 | -$7.11M derived: sum of 2 quarters · filed 2026-08-13 | -$11.68M 10-Q · filed 2025-11-12 | -$15.85M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$4.46M 10-Q · filed 2026-08-13 | -$9.03M 10-Q · filed 2026-08-13 | -$13.20M derived: sum of 3 quarters · filed 2026-08-13 | -$16.34M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$4.57M 10-Q · filed 2026-05-15 | -$8.74M derived: sum of 2 quarters · filed 2026-05-15 | -$11.89M derived: sum of 3 quarters · filed 2026-05-15 | -$16.00M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$7.31M derived: sum of 2 quarters · filed 2026-03-17 | -$11.42M derived: sum of 3 quarters · filed 2026-03-17 | -$15.37M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | -$3.14M 10-Q · filed 2025-11-12 | -$7.25M derived: sum of 2 quarters · filed 2025-11-12 | -$11.19M 10-Q · filed 2025-11-12 | -$15.37M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$4.11M 10-Q · filed 2025-08-13 | -$8.05M 10-Q · filed 2025-08-13 | -$12.23M derived: sum of 3 quarters · filed 2025-08-13 | -$16.48M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$3.94M 10-Q · filed 2025-05-14 | -$8.12M derived: sum of 2 quarters · filed 2025-05-14 | -$12.37M derived: sum of 3 quarters · filed 2025-05-14 | -$15.87M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$8.43M derived: sum of 2 quarters · filed 2025-03-13 | -$11.92M derived: sum of 3 quarters · filed 2025-03-13 | -$16.38M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | -$4.25M 10-Q · filed 2024-11-12 | -$7.74M derived: sum of 2 quarters · filed 2024-11-12 | -$12.20M 10-Q · filed 2024-11-12 | -$16.29M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$3.50M 10-Q · filed 2024-08-12 | -$7.95M 10-Q · filed 2024-08-12 | -$12.04M derived: sum of 3 quarters · filed 2024-08-12 | -$15.59M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$4.46M 10-Q · filed 2024-05-08 | -$8.54M derived: sum of 2 quarters · filed 2024-05-08 | -$12.09M derived: sum of 3 quarters · filed 2024-05-08 | -$15.96M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$7.64M derived: sum of 2 quarters · filed 2024-03-13 | -$11.51M derived: sum of 3 quarters · filed 2024-03-13 | -$14.91M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | -$3.55M 10-Q · filed 2023-11-06 | -$7.42M derived: sum of 2 quarters · filed 2023-11-06 | -$10.82M 10-Q · filed 2023-11-06 | -$14.04M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | -$3.87M 10-Q · filed 2023-08-14 | -$7.27M 10-Q · filed 2023-08-14 | -$10.49M derived: sum of 3 quarters · filed 2023-08-14 | -$13.86M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$3.40M 10-Q · filed 2023-05-11 | -$6.62M derived: sum of 2 quarters · filed 2023-05-11 | -$9.99M derived: sum of 3 quarters · filed 2023-05-11 | -$10.52M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$6.59M derived: sum of 2 quarters · filed 2023-03-17 | -$7.12M derived: sum of 3 quarters · filed 2023-03-17 | -$7.73M 10-K · filed 2023-03-17 | ||
| 2021-09-30 | -$3.37M 10-Q · filed 2022-11-10 | -$3.90M derived: sum of 2 quarters · filed 2022-11-10 | -$4.51M 10-Q · filed 2022-11-10 | -$5.28M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$528.64K 10-Q · filed 2022-08-08 | -$7.38M 10-Q · filed 2021-08-16 | -$1.14M 10-Q · filed 2022-08-08 | -$11.56M 10-Q · filed 2021-08-16 | -$1.91M derived: sum of 3 quarters · filed 2022-08-08 | -$3.46M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$613.98K 10-Q · filed 2022-05-12 | -$1.38M derived: sum of 2 quarters · filed 2022-05-12 | -$2.93M derived: sum of 3 quarters · filed 2022-05-12 | -$5.83M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$768.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$2.31M derived: sum of 2 quarters · filed 2022-03-21 | -$5.22M derived: sum of 3 quarters · filed 2022-03-21 | -$3.60M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$1.55M 10-Q · filed 2021-11-15 | -$4.45M derived: sum of 2 quarters · filed 2021-11-15 | -$2.83M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$2.90M 10-Q · filed 2021-08-16 | -$6.64M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |